Cefalex 250

Cefalex 250

202005-0184 • 4115 Views • Box of 24 packs x 1.5 g/pack with instruction sheet.

Each granules pack of CEFALEX 250 contains:

Active ingredient:

Cephalexin (Cephalexin monohyrate 262.95 mg) 250 mg

Cefalexin is a semisynthetic cephalosporin antibiotic for oral administration. Cefalexin is indicated in the treatment of the following infections due to susceptible micro-organisms:

  • Respiratory tract infections
  • Otitis media
  • Skin and soft tissue infections
  • Bone and joint infections
  • Genito-urinary tract infections, including acute prostatitis
  • Dental infections


Method of administration: 

  • Mix the medicine with a reasonable amount of water (approximately 5 mL for one sachet), stir well, and use immediately.

  • Should be taken on an empty stomach, 1 hour before meals.



  • The adult dosage ranges from 1-4 g daily in divided doses; 

  • Most infections will respond to a dosage of 500 mg every 8 hours. For skin and soft tissue infections, streptococcal pharyngitis and mild, uncomplicated urinary tract infections, the usual dosage is 250 mg every 6 hours, or 500 mg every 12 hours.

  • For more severe infections or those caused by less susceptible organisms, larger doses may be needed. If daily doses of cefalexin greater than 4 g are required, parenteral cephalosporins, in appropriate doses, should be considered.

The elderly and patients with impaired renal function

  • As for adults. Reduce dosage if renal function is markedly impaired (base on creatinine clearance)

Creatinine clearance (ClCr)

Recommended dose

≥ 60 mL/min

No dose adjustment is required

30 – 50 mL/min

No dose adjustment is required. The maximum daily dose should not exceed 1 g

15 – 29 mL/min

250 mg every 8 hours or every 60 hours

5 – 14 mL/min (*)

250 mg every 24 hours

1 – 4 mL/min (*)

250 mg every 48 hours or every 60 hours

(*) There is a lack of information on dose adjustment recommendations in patients on hemodialysis.

Paediatric population

The usual recommended daily dosage for children is 25-50 mg/kg (10-20 mg/lb) in divided doses. 

For skin and soft tissue infections, streptococcal pharyngitis and mild, uncomplicated urinary tract infections, the total daily dose may be divided and administered every 12 hours. 

For most infections the following schedule is suggested:

+ Children under 5 years: 125 mg every 8 hours.

+ Children 5 years and over: 250 mg every 8 hours.

In severe infections, the dosage may be doubled. In the therapy of otitis media, clinical studies have shown that a dosage of 75 to 100 mg/kg/day in 4 divided doses is required.

In the treatment of beta-haemolytic streptococcal infections, a therapeutic dose should be administered for at least 10 days.


Hypersensitivity to the active substance or to any of the excipients 

Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotic.


Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.

Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.

If an allergic reaction to cefalexin occurs, the drug should be discontinued, and the patient treated with the appropriate agents.

Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended

Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.

A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.

Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.

Excipient cautions

Sucrose: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Sodium benzoate: This medicine contains 10 mg sodium benzoate in each 1.5 g granules (corresponding to 1 pack), which must be used with caution in infants; Because benzoic acid (benzoate) is a metabolite of benzyl alcohol and large amounts of benzyl alcohol (≥ 99 mg/kg/day) have been associated with fatal poisoning (gasping syndrome) in infants; metabolic acidosis, respiratory failure, central nervous system dysfunction (convulsions, intracranial hemorrhage), hypotension, cardiovascular collapse. In addition, increase in bilirubinaemia following its displacement from albumin may increase neonatal jaundice which may develop into kernicterus (non-conjugated bilirubin deposits in the brain tissue).


36 months from the manufacturing date. After reconstitution: to be used within 14 days.

Aluminum package. Box of 12 packs x 1.5 g/pack with instruction sheet.

Aluminum package. Box of 24 packs x 1.5 g/pack with instruction sheet.

Aluminum package. Box of 30 packs x 1.5 g/pack with instruction sheet


Your comment

Similar products

Box of 2 blisters x 10 film-coated tablets
Contact Us
Box of 2 blisters x 10 film-coated tablets.
Contact Us
Box of 02 blisters x 10 capsules and 1 package insert.
Contact Us
Cefalex 500 (200 capsules)
Box of 01 bottle x 200 capsules
Contact Us
Cefalex 500
Al/PVC blister. Box of 10 blisters x 10 capsules
Contact Us
Bosgyno (Vaginal tablets)
Box of 01 strips x 06 Vaginal tablets
Contact Us
Bosgyno Plus
Box of 01 strips x 10 Vaginal tablets
Contact Us
Bosgyno (cream)
Box 1 tube x 10 g
Contact Us
Bostodroxil 500
Box of 10 blisters x 10 hard capsules with the package insert
Contact Us
Bostocef 300
Al/Al blisters. Box of 2 blisters x 10 tablets
Contact Us